KMPH - KMPH STOCK NEWS

KemPharm (NASDAQ: KMPH) announced that research on its ADHD treatment, AZSTARYS and serdexmethylphenidate (SDX), will be highlighted in presentations at two upcoming medical conferences in October, coinciding with ADHD Awareness Month. The conferences include the AACAP 2021 and Psych Congress, where findings from Phase 1 clinical trials will be discussed. The studies indicate that body weight is a key factor in the pharmacokinetics of d-methylphenidate exposure. KemPharm aims to present data that showcase AZSTARYS as a significant advancement in ADHD treatment.

KemPharm, a specialty pharmaceutical company, has announced its shares have been approved for listing on The Nasdaq Global Select Market, effective October 19, 2021, under the ticker symbol KMPH. This advancement marks a significant milestone following a year of substantial growth, highlighted by the launch of AZSTARYS, a novel ADHD medication. KemPharm's transition to the Global Select Market reflects its compliance with the highest listing standards, aiming to attract new investors and bolster its financial position.

KemPharm, a specialty pharmaceutical company, will have President and CEO Travis C. Mickle present at the Benzinga Healthcare Small Cap Conference from September 29-30, 2021. The presentation is scheduled for September 30 at 4:20 p.m., ET, and will be accessible to registered attendees via the conference's virtual platform. Following the event, attendees can find a recording of the presentation in the Investor Relations section of KemPharm's website. The company is known for its proprietary LAT® technology and pipeline targeting ADHD and CNS conditions.

KemPharm, a specialty pharmaceutical company focused on developing prodrugs, announced that Dr. Travis C. Mickle will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 28, 2021, at 1:20 p.m. ET. The presentation will be accessible via a webcast. Dr. Mickle and his team will also host virtual one-on-one meetings with investors. A recording of the presentation will be available after the event on KemPharm's website under the Investor Relations section.

KemPharm, a specialty pharmaceutical company, announced that Travis C. Mickle, Ph.D., will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available starting at 9:00 a.m. ET on September 13. Registered attendees can access the presentation through the conference's virtual platform.

KemPharm focuses on developing prodrugs for serious medical conditions using its proprietary LAT® technology. The company’s pipeline includes treatments for ADHD and CNS rare diseases.

KemPharm, Inc. (NASDAQ: KMPH) announced the appointment of Tamara A. Seymour to its Board of Directors and as Chair of the Audit Committee. With over 30 years in the life sciences industry, including 20 years as CFO, Seymour brings extensive experience to the company. She has served on the boards and audit committees of other biopharmaceutical companies. CEO Travis Mickle expressed optimism about Seymour's expertise contributing to KemPharm's growth and shareholder value. The company focuses on developing proprietary prodrugs for serious medical conditions, including ADHD and stimulant use disorder.

KemPharm, Inc. (NASDAQ: KMPH) reported its Q2 2021 results, highlighting a revenue of $12.0 million, up from $6.9 million in Q2 2020. The revenue increase was driven by a $10 million milestone payment for DEA scheduling of serdexmethylphenidate (SDX). The company experienced a net income of $6.2 million, or $0.18 per share, but faced a net loss of $10.7 million attributable to common stockholders due to a non-cash deemed dividend. Cash and equivalents stood at $132.3 million as of June 30, 2021.

KemPharm, a specialty pharmaceutical company, will host a conference call and live audio webcast on August 12, 2021, at 4:30 p.m. ET to discuss its Q2 2021 financial results. Interested participants can register for the call through an online form, receiving dial-in numbers and a passcode. The live audio webcast will be available via KemPharm's Investor Relations section, with an archive accessible for 90 days post-event. The company is focused on developing prodrugs for conditions such as ADHD and stimulant use disorder.

KemPharm, Inc. (NASDAQ: KMPH) has launched AZSTARYS™, a once-daily treatment for ADHD in patients aged six and older. Approved by the FDA in March 2021, AZSTARYS combines serdexmethylphenidate and immediate-release d-methylphenidate. Corium, Inc. will handle the U.S. commercialization. KemPharm anticipates that AZSTARYS will meet significant unmet needs in ADHD care, leveraging its unique prodrug technology. The ADHD market generated approximately $17.5 billion in revenue in 2019, with strong demand for innovative treatments.